Oncology Therapeutics Making Big in Coming Years
Jul 25, 2014
The industry’s 10 biggest-selling cancer drugs generated combined sales of $37.4billion in 2013, with Roche’s Rituxan, Avastin and Herceptin franchises extending their lead at the top of this league table. With combined sales of around $21 billion, these three drugs alone accounted for approximately 56 percent of the combined value of the 10 biggest-selling products.
| Drug Name | Company |
| Rituxan/MabThera | Roche, Pharmstandard |
| Avastin | Roche |
| Herceptin | Roche |
| Gleevec | Novartis |
| Alimta | Eli Lilly |
| Velcade | Johnson & Johnson, Takeda,Pharmstandard |
| Erbitux | Merck KGaA, Bristol-Myers Squibb |
| Lupron, Eligard | AbbVie and Takeda; Sanofi and Astellas Pharma |
| Zytiga | Johnson & Johnson |
| Revlimid |
Celgene, Pharmstandard |
Rituxan is developed by Roche’s Genentech which is the first monoclonal antibody treatment for cancer. And even after 15 years on the market, it continues to see its sales grow, up 6% for Roche in 2013. The drug is also approved to treat a number of cancers, including non-Hodgkin’s lymphoma and chronic lymphocytic leukemia (CLL), it also works against rheumatoid arthritis and generates about $1.2 billion a year in that category.
Downloads
Article in PDF
Recent Articles
- Eli Lilly strengthening its Gastroenterology portfolio post Acquisition of Morphic. Tracking comp...
- Hologic complements Focal; Allogene for IPO; Gamida, Novartis-backed cell therapy startup; Aduro ...
- Business Cocktail
- Antibody-Drug Conjugates Market Outlook, 2015 Report
- J&J’s COVID-19 Vaccine; GigaGen COVID-19 therapy; FDA approved Abbott’s POC test...
By comparing the sales of all the drugs the Roche company becomes the king of all the Pharmaceutical Companies involved in making oncology drugs.
Let’s have a look over the ranking on the basis of oncology sales 2013.
Roche has topped the ranking by its top selling drugs, followed by Amgen, Novartis, Celgene, Johnson and Johnson, Lily, Astrazeneca, Merck, BMS and Takeda.
Downloads
Article in PDF
Recent Articles
- Mitochondria destruction for Cancer Treatment; Atsena raises USD 55 Million financings; Novartis ...
- SEC scrutinizes; Acacia meets endpoint; Axovant’s dementia drug; Novartis expands; Aurobind...
- Lupin acquired; FDA grants approval; NATCO gets approval; Wockhardt Ltd. gets import alert; Paten...
- Top 7 Pharma Industry Leaders in 2020 By the Numbers
- JAK Inhibitors: New Lifeline for Hair Loss Treatment
